BCVA, anatomic improvements found with OPT-302 combination therapy for PCV

Video
Conference|ARVO

At ARVO 2022, Dr Jason S. Slakter presents data on the efficacy and safety of OPT-302 when combined with ranibizumab for polypoidal choroidal vasculopathy.

Emily Kaiser, editor of Modern Retina™, sits down with Dr Jason S. Slakter to discuss his ARVO 2022 presentation, “Efficacy and Safety of OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy.” OPT-302 (Opthea Limited) 2 mg combination therapy results indicated a safety profile consistent with the standard of care anti-VEGF-A monotherapy, but also indicated superior improvements in best-corrected visual acuity (BCVA) and anatomic improvements compared to monthly ranibizumab (Lucentis®) monotherapy in patients with polypoidal choroidal vasculopathy (PCV).

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Related Content
Site Logo

Interactive vision simulator illustrates the vision loss caused by retinal diseases

April 23rd 2024
Article

The online tool shows vision loss simulations for diabetic macular oedema, diabetic retinopathy, age-related macular degeneration and other retinal diseases

Professor Ramin Tadayoni, MD, PhD. Image courtesy of EURETINA

Retina community mourns sudden loss of Ramin Tadayoni, MD, PhD

April 22nd 2024
Article

Prof Tadayoni was a much-admired leader, researcher, surgeon and EURETINA President

The ZEISS Meditec logo in front of a graph showing a line up. Image credit: ©piter2121 – stock.adobe.com

Carl Zeiss Meditec AG announces completed acquisition of Dutch Ophthalmic Research Center

April 4th 2024
Article

Zeiss has secured regulatory approvals to acquire DORC and will shift focus to integration implementation

A detective looks through a magnifying glass at an eyeball. Image created with Canva AI.

Hemorrhagic unilateral retinopathy: No proven aetiology for rare condition

April 2nd 2024
Article

Multimodal imaging and a systemic work-up failed to identify any underlying disorder for the hemorrhages

A black background with a red line graph going down. Image credit: ©Who is Danny – stock.adobe.com

Increase in the incidence rate of conjunctival melanoma in Australia

March 28th 2024
Article

Investigators analysed the incidence and mortality rates from conjunctival melanoma cases over a 32-year period

Glasses with an overlay of digital data outputs on the surface. Image credit: ©Taiwo – stock.adobe.com

Exonate shares results from Phase Ib/IIa trial of EXN407 eye drops for DR and DME

March 27th 2024
Article

In addition to the primary safety and tolerability endpoints, the study also saw signals of biological response from EXN407

© 2024 MJH Life Sciences

All rights reserved.